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Abstract
Introduction Dichloroacetate (DCA) has been in clinical use for
the treatment of lactacidosis and inherited mitochondrial
disorders. It has potent anti-tumor effects both in vivo and in
vitro, facilitating apoptosis and inhibiting proliferation. The pro-
apoptotic and anti-proliferative properties of DCA prompted us
to investigate the effects of this compound in arthritis.
Methods In the present study, we used DCA to treat murine
collagen type II (CII)-induced arthritis (CIA), an experimental
model of rheumatoid arthritis. DBA/1 mice were treated with
DCA given in drinking water.
Results Mice treated with DCA displayed much slower onset of
CIA and significantly lower severity (P < 0.0001) and much
lower frequency (36% in DCA group vs. 86% in control group)
of arthritis. Also, cartilage and joint destruction was significantly
decreased following DCA treatment (P  = 0.005). Moreover,
DCA prevented arthritis-induced cortical bone mineral loss. This
clinical picture was also reflected by lower levels of anti-CII
antibodies in DCA-treated versus control mice, indicating that
DCA affected the humoral response. In contrast, DCA had no
effect on T cell- or granulocyte-mediated responses. The
beneficial effect of DCA was present in female DBA/1 mice only.
This was due in part to the effect of estrogen, since
ovariectomized mice did not benefit from DCA treatment to the
same extent as sham-operated controls (day 30, 38.7% of
ovarectomized mice had arthritis vs. only 3.4% in sham-operated
group).
Conclusion Our results indicate that DCA delays the onset and
alleviates the progression of CIA in an estrogen-dependent
manner.
Introduction
The pyruvate dehydrogenase activator dichloroacetate (DCA)
is a small molecule that has been used in humans for decades
as a treatment for acquired and congenital forms of lactacido-
sis by shifting pyruvate metabolism from cytoplasmic lactate
production to oxidative production of acetyl-CoA in the mito-
chondria [1]. Most recently, DCA was found to act as an effi-
cient tumor growth inhibitor, both in vitro and  in vivo, by
shifting glucose metabolism from glycolysis to glucose oxida-
tion in malignant cells. This shifting results in the release of
pro-apoptotic mediators and decreases proliferation in malig-
nant cells, thus eliminating active tumor cells while leaving the
normal cells unaffected [1].
Rheumatoid arthritis (RA) is a systemic autoimmune disease
characterized by chronic joint inflammation [2]. The preva-
lence of RA is 0.5% to 1% of the population worldwide.
Females have a higher incidence (3:1) than males. Several
lines of evidence show that the female hormone estrogen
affects both the incidence and the progression of RA in
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humans [3,4] and in animal models [5,6]. RA is characterized
by synovial cell proliferation and infiltration of inflammatory
cells to the synovium. Cytokine production by these cells (for
example, tumor necrosis factor-alpha [TNF-α] and interleukin
[IL]-1, IL-6, and IL-17) plays a pivotal role in RA [7]. These
cytokines, notably TNF [8] and IL-6 [9], may promote the
development of osteoclasts [10], which increases bone ero-
sion and systemic bone loss [11].
Because the cause of RA is complex and elusive, it continues
to present therapeutic challenges, especially erosive arthritis.
Murine collagen II (CII)-induced arthritis (CIA) is a widely used
experimental model of RA and shares many histopathological
features of the human counterpart [12]. It is usually used to
investigate mechanisms relevant to RA as well as new anti-
arthritic treatments [13]. As in the case of RA, CIA is primarily
an autoimmune disease of the joints [14] with increased ang-
iogenesis, inflammatory cell infiltration, synovial hyperplasia,
and bone erosion. Because of the anti-proliferative and pro-
apoptotic properties of DCA, we hypothesized that DCA may
inhibit the development of arthritis in CIA. To this end, DCA
was added to drinking water at the time of induction of CIA.
Our results suggest that DCA significantly delays the onset
and development of destructive arthritis in female DBA/1 mice.
The protective effect of DCA was mediated in part via estro-
gen-dependent pathways.
Materials and methods
Mice
DBA/1 mice (Taconic Europe A/S, Ry, Denmark), 6 to 8 weeks
old, were used for CIA experiments. For the delayed-type
hypersensitivity (DTH) experiment, 6 to 8 week old mice were
used. All of the mice were maintained in the animal facility of
the Department of Rheumatology and Inflammation Research,
University of Gothenburg, Sweden, in accordance with the
local ethics board animal husbandry standards. Mice were
housed up to 10 animals per cage under standard conditions
of light and temperature and fed with standard laboratory
chow ad libitum.
Collagen II-induced arthritis
Chicken CII (Sigma-Aldrich, St. Louis, MO, USA) was dis-
solved at a concentration of 2 mg/ml in 0.1 M acetic acid and
then emulsified in an equal volume of complete Freund's adju-
vant (Sigma-Aldrich). Arthritis was induced by intradermal
injection of DBA/1 mice at the base of the tails with 100 μL of
the emulsion. Booster immunization containing 100 μg of CII
in incomplete Freund's adjuvant (Sigma-Aldrich) was adminis-
tered 21 days after the priming. The experiments were termi-
nated in 6 to 8 weeks.
Dichloroacetate treatment
CIA was used to investigate the effect of DCA (sodium DCA
99% purity; BuyDCA, Sonora, CA, USA) on arthritis. DCA was
administered by dissolving it in the drinking water. Control
mice were given water only. The average amount of DCA per
mouse taken was determined by measuring the volume of
Table 1
Distribution of mice in dichloroacetate treatment of collagen II-induced arthritis
Gender Treatment Number of mice Arthritis indexa
First experiment Female DCA 4 3/4 (0.75)
Female Water 4 30/4 (7.5)
Male DCA 6 35/6 (5.8)
Male Water 5 22/5 (4.4)
Second experiment Female DCA 10 6/10 (0.6)
Female Water 10 34/10 (3.4)
Male DCA 10 31/10 (3.1)
Male Water 10 39/10 (3.9)
Third experiment Female DCA 8 7/8 (0.9)
Female Water 8 38/8 (4.75)
OVX experiment 1 OVX DCA 10 16/10 (1.6)
Sham DCA 10 3/10 (0.3)
OVX experiment 2 OVX DCA 21 63/21 (3.0)
Sham DCA 19 23/19 (1.2)
aArthritis index at termination of experiments. DCA, dichloroacetate; OVX, ovariectomy; Sham, sham-operated.Available online http://arthritis-research.com/content/11/5/R132
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DCA solution that mice consumed in each cage. We calcu-
lated and adjusted the concentration of DCA required to
achieve a daily dose of 0.3 mg or 3 mg DCA/mouse per day.
DCA was provided in the drinking water from day 0 of all
experiments. The experiment was repeated three times as out-
lined in Table 1. To study the impact of estrogen on DCA-
mediated effects, endogenous estrogen production in female
DBA/1 mice was blocked by ovariectomy (OVX). Sham-oper-
ated mice were used as controls. DBA/1 mice were regularly
weighed from the day of priming and checked for the develop-
ment of arthritis after booster immunization. When the experi-
ments were terminated, blood was drawn for serological
analyses. Paws were processed for histological analyses.
Clinical evaluation of arthritis
All of the DBA/1 mice were inspected every second or third
day after booster to assess the presence of arthritis. To evalu-
ate the intensity of arthritis, a clinical scoring system of 0 to 3
points for each paw was used: 0, no sign of inflammation; 1,
mild swelling or erythema or both; 2, moderate swelling and
erythema; and 3, marked swelling and erythema. The arthritic
index for each mouse was constructed by summing up the
scores of all four limbs.
Delayed-type hypersensitivity reaction
To assess the impact of DCA on a T cell- and macrophage-
dependent inflammatory response [15,16], the DTH reaction
was performed. Thirty female mice were divided into three
groups (10 mice per group). Two groups were provided DCA
in drinking water (0.3 and 3 mg/mouse per day, respectively).
The control group was provided water only. After 2 days, all of
the mice were immunized by epicutaneous application of 150
μL of a mixture of ethanol acetone (2:1) containing 3% (vol/
vol) oxazolone (OXA) (Sigma-Aldrich) on the abdomen skin.
One week after the priming, the right ears were challenged on
both sides by topical application of 30 μL of 1% OXA, which
was dissolved in olive oil. Thirty microliters of olive oil only was
applied to the left ears as vehicles. The intensity of DTH reac-
tion was examined as previously described [17].
Olive oil-induced inflammation
Olive oil-induced skin inflammation is granulocyte-mediated
but T cell- and monocyte-independent [18]. A single intrader-
mal injection of olive oil into mouse footpad induces massive
infiltration of polymorphonuclear cells, which give rise to a
localized footpad swelling. The thickness of footpad can be
measured and relates to severity of the inflammatory process
[19]. Thirty microliters of olive oil (Apoteksbolaget, Göteborg,
Sweden) was injected intradermally in a hind foot dorsum of
mice. Footpads were measured before and 24 hours after
injection using an Oditest spring caliper (Kröplin, Schluchtern,
FRG). The footpad swelling was expressed as footpad
increased thickness (in millimeters) after injection and was
scored as described previously [20].
Analyses of hormone, antibody, and cytokine levels
The level of serum hormones was analyzed by the following
radioimmunoassays: insulin-like growth factor (IGF1) (Mediag-
nost, Reutlingen, Germany), testosterone (MP Biomedicals,
Irvine, CA, USA), and cortisol (CIS Bio International, Marcoule,
France). Uteri were weighed as an indirect indicator of estra-
diol level [21]. Anti-CII antibody analyses were performed as
previously described [22]. IL-6 levels in sera were analyzed as
described before [23].
Histological examination
All four paws from DBA/1 mice were excised, followed by rou-
tine fixation, decalcification, and paraffin embedding. Tissue
sections were stained with hematoxylin/eosin. The sections
were studied by a blinded examiner regarding synovitis and
erosion of bone/cartilage. Synovial hypertrophy was defined
as a membrane thickness of more than two cell layers [23]. A
histological scoring system was used: 1, mild; 2, moderate;
and 3, severe synovitis or bone erosion [24]. Knee joints,
ankles, toes, elbows, wrists, and hands were examined. A
mean score from all of the inspected paws for each animal was
calculated [25].
Impact of dichloroacetate on bone mineral density
The left femurs from DBA/1 mice were fixed in 4% (vol/vol)
buffered formaldehyde for 3 days and then replaced by 70%
(vol/vol) alcohol until analyses of bone mineral density (BMD)
were performed. A peripheral quantitative computed tomogra-
phy (pQCT) scan with a Stratec pQCT XCT Research M (Nor-
land, Fort Atkinson, WI, USA) was used as previously
described [26]. Trabecular BMD was analyzed with a meta-
physeal scan at a point located at a distance of 3% of the
length of the femur from the distal growth plate. The inner 45%
of the area was defined as the trabecular bone compartment.
Cortical bone parameters were determined with a middiaphy-
seal scan, which contained only cortical bone.
Statistical analysis
Statistical analyses were performed by using the Mann-Whit-
ney U test and the chi-square test. Values are reported as
median ± 10% to 90% range. A P value of less than 0.05 was
considered significant.
Results
Effect of dichloroacetate on development of collagen II-
induced arthritis
To evaluate whether DCA had an effect on the development of
CIA, male and female DBA/1 mice were provided drinking
water with or without DCA from the priming day until the exper-
iment was terminated. At a dose of 3 mg DCA/mouse per day,
for female DBA/1 mice, none of the 22 mice that drank DCA
had signs of arthritis 37 days after the priming with CII,
whereas most of the control mice (16 of 22, or 73%) (P <
0.0001) already had ongoing arthritis (Figure 1a). Female mice
that drank DCA had a much lower severity of arthritis (FigureArthritis Research & Therapy    Vol 11 No 5    Bian et al.
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Figure 1
Frequency, severity of arthritis, bone destruction, and weight change in collagen II (CII)-induced arthritis mice treated with dichloroacetate (DCA) (3  mg/mouse per day) or water Frequency, severity of arthritis, bone destruction, and weight change in collagen II (CII)-induced arthritis mice treated with dichloroacetate (DCA) (3 
mg/mouse per day) or water. (a) DCA effect on frequency of arthritis in both female and male CII arthritis mice. (b) DCA treatment on both female 
and male mice in regard to severity of arthritis. (c) Synovitis and bone erosion in CII-immunized DBA/1 with or without DCA treatment. (d) Weight 
change in DCA-treated mice and water controls during the course of CII-induced arthritis experiments. Values from three independent experiments 
were pooled. The DCA-treated group and the water-drinking group each contained 22 mice.Available online http://arthritis-research.com/content/11/5/R132
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1b). For male mice, there was no difference between the DCA-
drinking group and the water group in regard to the onset of
arthritis and its severity. In the dose of 0.3 mg DCA/mouse per
day, we did not find any impact of DCA on the development
and course of CIA (data not shown).
Histological sections from female mice confirmed that the
DCA group had a lower severity of arthritis. Notably, the
destruction of bone and cartilage was significantly diminished
in the DCA-drinking group compared with the control group
(Figures 1c and 2). In contrast, there was no significant differ-
ence in male mice between the two groups. Importantly, DCA-
treated mice did not show decreased weight gain as com-
pared with control mice (Figure 1d), indicating that DCA was
not toxic. In fact, female mice receiving DCA gained slightly
more weight than their controls.
Effect of dichloroacetate on inflammatory immune 
responses
A potential mechanism by which DCA could suppress CIA is
the blocking of anti-CII antibody production. Anti-CII antibody
levels and serum IL-6 were analyzed in serum obtained at the
termination of experiments. In female mice, but not in male
mice, circulating anti-CII IgG antibody levels were significantly
decreased in the DCA-drinking group compared with the
water group (P = 0.04) (Figure 3a). The serum IL-6 level in the
DCA-drinking group was lower than in the water group, but the
data did not reach statistical significance (P = 0.06) (Figure
3b). Thus, the anti-inflammatory effect of DCA on arthritis is
accompanied by lower levels of anti-CII antibodies.
Impact of dichloroacetate on in vivo cell-mediated 
inflammatory responses
DTH is a T cell-mediated immune reaction. To test the effect
of DCA on DTH, DCA-treated mice and water controls were
epicutaneously immunized and challenged with OXA. DTH
reactivity was registered by measuring the increase in ear
thickness 24 hours after the challenge. We did not find any
significant differences in regard to the severity of DTH
between DCA-treated mice and their controls (data not
shown). Likewise, DCA had no effect on the granulocyte-
dependent olive oil-induced inflammation (data not shown).
Dichloroacetate treatment ameliorates the cortical bone 
loss induced by arthritis
To evaluate whether the ameliorative effect of DCA on CIA
also was reflected in the protection of arthritis-induced bone
loss, the left femur of each mouse was subjected to a pQCT
scan at the termination of CIA. Mice immunized with CII and
treated with DCA displayed significantly higher cortical bone
mineral content than did the water-drinking group (P = 0.001)
(Figure 4a). Likewise, thickness of cortical bone (P = 0.039)
(Figure 4b) and cortical bone area (P = 0.01) (Figure 4c) were
significantly higher in the DCA-treated group. No differences
were observed with respect to total BMD and trabecular BMD
between the DCA-drinking group and their water controls
(Figure 4d, e).
Impact of ovariectomy on dichloroacetate treatment of 
arthritis
Because only female mice responded to DCA therapy, we
hypothesized that the beneficial effect of DCA on arthritis was
related to estrogen. To evaluate the importance of estrogens,
one group of DBA/1 mice was ovariectomized (OVX) and
another group had sham surgery. After 1 week, both groups
were primed and booster - immunized with CII and treated with
DCA (3 mg DCA/mouse per day) as previously described. On
day 30, 12 of 31 mice in the OVX group had signs of arthritis
(38.7%) compared with only 1 of 29 mice in the sham controls
(3.4%) (P = 0.001). On day 34, 17 of 31 in the OVX group
had arthritis (54.8%) but only 5 of 29 in the sham-operated
group did (17.2%) (P = 0.003). When the experiment was ter-
Figure 2
Micrographs of tarsal joints from collagen II-immunized female and male  DBA/1 mice Micrographs of tarsal joints from collagen II-immunized female and male 
DBA/1 mice. (a) Representative image of a tarsal joint from a female 
water-drinking mouse. (b) Representative image of a tarsal joint from a 
female dichloroacetate (DCA)-drinking mouse (3 mg DCA/mouse per 
day). (c) Representative image of a tarsal joint from a male water-drink-
ing mouse. (d) Representative image of a tarsal joint from a male DCA-
drinking mouse (3 mg DCA/day). Arrowheads indicate erosion of bone 
and cartilage. Scale bar = 100 μm. B: bone; C: cartilage; JC: joint cav-
ity; S: synovitis.Arthritis Research & Therapy    Vol 11 No 5    Bian et al.
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minated on day 38, 19 of 31 mice in the OVX group had devel-
oped arthritis (61.3%). In contrast, only 10 of 29 mice in the
sham-operated group (34.5%) had signs of arthritis (P = 0.04)
(Figure 5a). The sham-operated group also had much less
severe arthritis than the OVX group (P = 0.006) (Figure 5b).
Histological analysis showed that the OVX group had synovitis
(P = 0.004) and bone erosion (P = 0.01) that were signifi-
cantly more severe compared with sham-operated controls
(Figure 5c). But no difference was found between the OVX
group and the sham-operated group in regard to weight
changes (data not shown).
Although OVX mice and sham-operated mice had different
arthritis responses following DCA treatment, we did not find
any difference between the OVX group and the sham group in
regard to level of IL-6 (OVX: median 76 pg/mL, range 20 to
1,032 pg/mL versus sham: median 111.2 pg/mL, range 30 to
348.2 pg/mL) and anti-CII antibodies (optical density: OVX:
median 0.91, range 0.37 to 1.32 versus sham: median 0.84,
range 0.30 to 1.69). As an indirect indicator of estrogen levels,
the weight of uteri from DCA- and water-treated intact female
mice was recorded. No difference was found between the
DCA group and their controls (DCA: median 50 mg, range 26
to 111 mg, n = 8 versus water: median 49 mg, range 15 to
104 mg, n = 8). We also measured the level of testosterone.
There was no significant difference between the DCA group
and the control group (Data not shown).
Discussion
DCA delays the onset of CIA and at the same time alleviates
the progress of CIA. Interestingly, this outcome is observed in
female mice only. Female DBA/1 mice treated with DCA had
Figure 3
Dichloroacetate (DCA) impact on in vivo inflammatory immune response Dichloroacetate (DCA) impact on in vivo inflammatory immune response. (a) IgG anti-collagen II antibody levels from the DCA-drinking group and 
the water-drinking group. (b) Serum pro-inflammatory cytokine intereukin-6 (IL-6) levels from DCA-drinking mice and water controls. Values from two 
experiments were pooled. The DCA-drinking group and the water-drinking group each contained 14 mice. OD: optical density.Available online http://arthritis-research.com/content/11/5/R132
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a significant slower onset and less severe arthritis compared
with water-treated controls. Importantly, the destructive action
of inflammation on bone was almost totally inhibited in mice
provided with DCA. The results of this study reveal for the first
time that destructive arthritis can be inhibited by DCA admin-
istration. Our results also suggest that estrogen plays an
important role in the beneficial effect of DCA.
DCA is a well-established drug used for the treatment of lactic
acidosis. It also exhibits efficient anti-tumor properties due to
its pro-apoptotic and anti-proliferative effects without visibly
affecting non-cancerous cells or eliciting systemic toxicity [1].
RA, like a malignant tumor, is also characterized by increased
cell proliferation. We therefore wanted to evaluate whether
DCA could prevent the development of arthritis in a model of
Figure 4
Dichloroacetate (DCA) effect on bone mineral density (BMD) (female mice only) Dichloroacetate (DCA) effect on bone mineral density (BMD) (female mice only). (a) Cortical bone mineral content in mice treated with DCA or 
water. (b) The thickness of cortical bone in the DCA-drinking group and the water-drinking group. (c) Cortical bone area in the DCA-drinking group 
and the water-drinking group. (d) Total BMD measured in the DCA group and water controls. (e) Trabecular BMD in the DCA-treated group and 
water controls. One experiment was performed with eight female mice in the DCA-drinking group and eight female mice in the control group.Arthritis Research & Therapy    Vol 11 No 5    Bian et al.
Page 8 of 10
(page number not for citation purposes)
RA. To this end, we treated CIA in DBA/1 mice with DCA. We
found that DCA can ameliorate arthritis potently, but only in
female mice.
How does DCA abolish the development of chronic destruc-
tive inflammation in CIA? B cells are important in the patho-
genesis of RA by producing auto-antibodies and in T-cell
activation [27]. Antibodies to CII have been detected in serum
and synovial fluid of patients with RA [28,29]. As in RA, anti-
CII antibody production contributes to the development of CIA
[30,31]. The beneficial effect of DCA on arthritis is likely due
to the down-regulation of B cells producing anti-CII antibodies
because DCA-treated mice displayed significantly lower levels
of anti-CII antibodies (Figure 3a). This may be a direct effect of
DCA or mediated via reduction of pro-inflammatory cytokines.
IL-6 is a pro-arthritogenic cytokine that affects B cells by pro-
moting plasma cell differentiation, antibody production, and
class switch [32-34]. A tendency toward lower serum levels of
IL-6 was observed in DCA-treated female mice compared with
water-treated mice (Figure 3b), which thus reflects a possible
role of IL-6 in DCA-mediated inhibition of anti-CII antibody pro-
duction. We could not show any effect of DCA on T cell-medi-
ated inflammation (DTH) or granulocyte-mediated
inflammation (olive oil-induced), suggesting that the observed
beneficial effect is through humoral immunity, as indicated by
the effect on anti-CII antibody production.
Because only female DBA/1 mice displayed amelioration of
arthritis in response to DCA treatment, female hormones such
as estrogen may play a role. A role of estrogens in RA is sug-
gested by the therapeutic effect of estradiol in menopausal
women with RA, a group of patients characterized by low lev-
els of estrogens and high incidence of RA [3,5,35,36]. In addi-
tion, estradiol has both prophylactic and therapeutic effects on
arthritis development in CIA [37]. To test the hypothesis,
endogenous estrogens were removed by OVX. The OVX
group treated with DCA had an earlier onset of disease, more
frequent and more severe arthritis, and more synovitis and
bone destruction compared with the sham-operated group
treated with DCA, which had intact estrogen production. A
confounding factor is the fact that the OVX treatment in itself
may worsen CIA [36], which could possibly mask anti-inflam-
matory effects of DCA. But the net effect of DCA on sham ver-
sus OVX mice is of several magnitudes greater than the effect
of OVX on arthritis. DCA ameliorates arthritis by decreasing
the frequency of arthritis by at least 40% in sham versus OVX
mice (Figure 5a, day 38) and the severity by at least 65% (Fig-
ure 5b, days 37 and 38), whereas the earlier reported aggra-
vating effect of OVX on arthritis severity is 20% and the effect
on arthritis frequency is minimal or non-existent [36]. This sug-
gests that the observed difference between mice unable to
produce estrogens and water controls is indeed due to the
DCA treatment. An ameliorating effect of estrogens on arthritis
has been demonstrated in both mice and humans [3,5,35,36].
However, the effect of DCA is probably not via increased pro-
duction of estrogens as DCA treatment did not cause
increased uterus weight. Rather, DCA elicits its effect by
affecting estrogen signaling.
The beneficial effect of DCA on CIA may not be entirely
dependent on estrogens. This is supported by the fact that
DCA-treated mice unable to produce estrogen (OVX mice)
had a lower frequency of arthritis (61.3%) than water-treated
mice (86.4%) (Figures 5a and 1a, respectively). As only female
mice benefited from DCA treatment, this observation indicates
that DCA has some estrogen-independent but gender-
dependent effects on inflammation. Also, the difference in
response to DCA could be due to the fact that male hormones
may inhibit the DCA effect.
Figure 5
Impact of ovariectomy (OVX) on dichloroacetate (DCA) treatment of  arthritis Impact of ovariectomy (OVX) on dichloroacetate (DCA) treatment of 
arthritis. Frequency (a) and severity (b) of arthritis in DCA-treated ova-
riectomized mice and in sham-operated mice treated with DCA. (c) His-
tological index of OVX and sham-operated mice treated with DCA. 
Results of two experiments were pooled with 31 OVX mice and 29 
sham-operated mice.Available online http://arthritis-research.com/content/11/5/R132
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Previous studies of DCA in inflammation have not focused on
the effect on bone density. Our results clearly indicate that
DCA can prevent cortical bone mineral loss in female mice in
CIA (Figure 4a) as a result of increased cortical thickness (Fig-
ure 4b). This is in line with a recent study showing that down-
regulation of arthritis severity will lead to not only absence of
local erosion (that is, in cartilage and subchondral bone) but
also systemic effects on BMD [36]. We believe that the bene-
ficial effect of DCA on bone is mediated by a combination of
estrogen-dependent effects and the decrease of the inflamma-
tory response manifested by a reduced level of anti-CII anti-
bodies. First, estrogen is important for bone maintenance and
may provide protection from bone destruction in arthritis
[3,5,35,36]. The role of estrogen in the DCA-mediated effect
was demonstrated by the fact that female mice, but not male
or OVX-treated female mice, benefited from DCA treatment.
Second, the lower levels of anti-CII antibodies found in DCA-
treated animals may also prevent bone destruction as anti-CII
antibodies induce bone erosions in the CIA model [38]. Such
bone erosions may be mediated via anti-CII antibody-depend-
ent C3 recruitment to the cartilage surface, which will initiate
an immunological attack, eventually leading to bone destruc-
tion [39]. The DCA-mediated reduction of the pro-inflamma-
tory cytokine IL-6 may also contribute to bone protection as IL-
6 has potent effects on cartilage and bone destruction [40].
The effect of DCA on cortical bone may also be indirect. As
animals have less arthritis, they are more prone to physical
activity, which may account for the difference in cortical BMD
[41] between treated and non-treated animals (Figure 4). This
notion is furthermore in line with the observation that the effect
of DCA on bone was mainly on cortical bone, and not on
trabecular bone, which is less affected by physical training
[42].
Conclusions
Here, we show for the first time that DCA, a potent drug
against lactacidosis, also can protect against the development
of arthritis in female mice. DCA ameliorates the development
of destructive arthritis in part via estrogen and in part via direct
down-modulation of inflammation. This warrants future studies
of the therapeutical effect of DCA on already established
arthritis. The recent long-term clinical trial of oral DCA in chil-
dren showed that DCA is well tolerated and safe [43], sug-
gesting that DCA can be a potential tool for treating female
patients with RA.
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